Neutral
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
C4 Therapeutics (NASDAQ:CCCC) surpassed analyst revenue expectations but reported a statutory loss smaller than predicted. Despite analysts cutting 20...